Search results for " systemic"

showing 10 items of 201 documents

Correlation between cell free DNA levels and medical evaluation of disease progression in systemic lupus erythematosus patients

2014

High levels of cell free DNA (cfDNA) in human blood plasma have been described in patients with autoimmune diseases. The aim of this study was to determine the levels of cfDNA in systemic lupus erythematosus (SLE) patients and to assess fluctuations of cfDNA concentrations compared to the course of disease progression under standard treatment. Therefore, nuclear cfDNA concentrations in plasma were measured in 59 SLE patients and 59 healthy controls. Follow-up blood plasma was collected from 27 of the 59 SLE patients. Patients were characterised by clinical parameters (antinuclear antibodies (ANA), anti-dsDNA-antibodies, C3, C4, and CRP), SLE disease activity index (SLEDAI) and medical thera…

AdultMalemedicine.medical_specialtyAnti-nuclear antibodyImmunologyBiologyGastroenterologyDisease courseimmune system diseasesInternal medicineBlood plasmamedicineHumansLupus Erythematosus SystemicIn patientskin and connective tissue diseasesCell-Free SystemStandard treatmentDisease progressionMedical evaluationDNACell-free fetal DNAImmunologyDisease ProgressionFemaleBiomarkersCellular Immunology
researchProduct

Serum surfactant protein D and exhaled nitric oxide as biomarkers of early lung damage in systemic sclerosis

2017

Background Interstitial lung disease (ILD) complicates the course of systemic sclerosis (SSc), representing the main cause of death in these patients. The identification of parameters that can predict the early onset and progression of ILD in SSc represents an unmet need in clinical practice. The study was designed to explore whether the surfactant proteins (SP) A and D may be used as noninvasive tools for the early identification of ILD in SSc. Alveolar exhaled nitric oxide (NO) was investigated as a surrogate marker of distal inflammation. Methods Unselected consecutive subjects newly diagnosed with scleroderma and subjects free of respiratory and systemic diseases were recruited. All pat…

AdultMalemedicine.medical_specialtyBreath TestSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologySclerodermaScleroderma03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineDLCOInternal medicineMedicineHumansRespiratory systemLungScleroderma Systemicbusiness.industryPulmonary surfactant-associated proteinMedicine (all)SystemicInterstitial lung diseaseSurfactant protein DNitric oxideGeneral MedicineBiomarkerrespiratory systemmedicine.diseasePulmonary Surfactant-Associated Protein Dmedicine.anatomical_structure030228 respiratory systemBreath Tests030220 oncology & carcinogenesisLung diseaseExhaled nitric oxideFemalebusinessInterstitialLung Diseases InterstitialBiomarkersHuman
researchProduct

Esophageal dysfunction and its pathogenesis in progressive systemic sclerosis

1978

In 25 patients with progressive systemic sclerosis esophageal involvement was studied prospectively by analysing subjective symptoms and radiological and manometric criteria. In all patients abnormal motility could be demonstrated by X-ray and/or manometry: radiologically in 18 (72%), manometrically in 22 (88%) cases. Dysphagia was present only in 11 patients (44%). Six patients (24%) had no subjective symptoms in spite of severe objective esophageal abnormalities. Therefore, the absence of esophageal symptoms does not exclude advanced affliction of the esophagus. To determine the pathogenesis of esophageal dysfunction the effects of 3.5 microgram/kg carbachol and of 0.6 microgram/kg pentag…

AdultMalemedicine.medical_specialtyCarbacholManometryGastroenterologySclerodermaPathogenesisEsophagusAtrophyInternal medicineDrug DiscoverymedicineHumansEsophagusGenetics (clinical)AgedPeristalsisScleroderma Systemicbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseDysphagiaSurgeryPentagastrinmedicine.anatomical_structureMolecular MedicineCarbacholFemalePentagastrinPeristalsismedicine.symptomDeglutition Disordersbusinessmedicine.drugKlinische Wochenschrift
researchProduct

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis:A Randomized, Placebo-Controlled, Phase II Study

2017

Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). Methods Patients with SSc-related RP were randomized 1:1 to placebo (n = 38) or selexipag (n = 36) in individualized doses (maximum of 1,600 μg twice daily) during a 3-week titration period. The primary end point was the weekly average number of RP attacks during the study maintenance period, analyzed using a Bayesian approach with a negative binomial model adjusted for baseline number of RP attacks. Other outcome measures included Raynaud's Condition Score (RCS), RP attack duration, and treat…

AdultMalemedicine.medical_specialtyImmunologyPhases of clinical researchSelexipagPlaceboSeverity of Illness Indexlaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodRheumatologyRandomized controlled triallawInternal medicineAcetamidesSeverity of illnessClinical endpointHumansImmunology and AllergyMedicine030212 general & internal medicineAdverse effectAntihypertensive Agents030203 arthritis & rheumatologyScleroderma Systemicbusiness.industryBayes TheoremRaynaud DiseaseMiddle AgedClinical trialTreatment OutcomechemistryPyrazinesFemalebusiness
researchProduct

A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study.

2015

Objective: Qualitative capillaroscopy patterns in juvenile- and adult-onset systemic sclerosis (SSc) were studied in adulthood using data from the EULAR Scleroderma Trials and Research (EUSTAR) database. Methods: Data collected between June 2004 and April 2013 were examined with focus on capillaroscopy. In this retrospective exploratory study, series of patients with juvenile-onset SSc were matched with series of adult-onset SSc having the same gender and autoantibody profile. Results: 30 of 123 patients with juvenile-onset and 2108 of 7133 with adult-onset SSc had data on capillaroscopy. Juvenile-onset SSc showed scleroderma pattern more frequently than adult-onset SSc (93.3% and 88%). The…

AdultMalemedicine.medical_specialtyPathologyAdolescentKlinikai orvostudományokBiochemistryJuvenile systemic sclerosiSclerodermaMicroscopic AngioscopySystemic sclerosiScleroderma LocalizedYoung AdultMedicineJuvenileHumansYoung adultAge of Onsetskin and connective tissue diseasesChildNailfold CapillaroscopyVideocapillaroscopyAgedRetrospective StudiesEUSTARScleroderma Systemicintegumentary systemCapillaroscopybusiness.industrySimilar distributionMicrocirculationAutoantibodyRetrospective cohort studyOrvostudományokCell BiologyMiddle Agedmedicine.diseaseDermatologyCapillariesNailfold capillaroscopyFemaleAge of onsetCardiology and Cardiovascular MedicinebusinessCapillaroscopy; EUSTAR; Juvenile systemic sclerosis; Microcirculation; Nailfold capillaroscopy; Systemic sclerosis; Videocapillaroscopy; Biochemistry; Cardiology and Cardiovascular Medicine; Cell BiologyMicrovascular research
researchProduct

Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects.

2008

Systemic lupus erythematosus (SLE) is characterised by increased venous and arterial thrombotic risk. Although antiphospholipid antibodies (APAs) have been shown to be related with thrombotic tendency in these patients, in more than 40% of them, thrombosis occurs without the presence of such antibodies. We analysed the association of venous and arterial thrombotic events with acquired (anticardiolipin antibodies (ACAs) and lupus anticoagulant (LA)) and inherited (antithrombin (AT), protein C (PC), protein S (PS) deficiencies, factor V Leiden and the prothrombin G20210A mutation), thrombophilic risk factors in 86 SLE patients and 89 healthy controls. Patients showed a higher significant perc…

AdultMalemedicine.medical_specialtyPhysiologyGastroenterologyProtein SRisk FactorsPhysiology (medical)Internal medicinemedicineFactor V LeidenHumansLupus Erythematosus SystemicRisk factorLupus anticoagulantbiologybusiness.industryAntithrombinThrombosisHematologyBlood ProteinsMiddle Agedmedicine.diseaseThrombosisVenous thrombosisAntibodies AnticardiolipinLupus Coagulation InhibitorImmunologyMutationbiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessProtein Cmedicine.drugClinical hemorheology and microcirculation
researchProduct

Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol

2006

Objectives: to evaluate the clinical efficacy and the effects on the quality of life of Iloprost, a prostacyclin analogue, used, according to a new protocol, in patients with Raynaud’s phenomenon secondary to Systemic Sclerosis. Methods: in this randomized study we treated 30 patients with Iloprost given by intravenous infusion, at progressively increasing doses (starting from 0.5 ng/Kg/min up 2 ng/Kg/min) over a period of 6 hours a day for ten days in two consecutive weeks, with repeated cycles at regular intervals of three months for 18 months. The results were compared with those obtained in 30 other patients, who had received the same drug but with different posologic schemes. Results: …

AdultMalemedicine.medical_specialtyTime FactorsVasodilator AgentsSeverity of Illness IndexDrug Administration ScheduleSclerodermalaw.inventionRheumatologyRandomized controlled trialQuality of lifelawSeverity of illnessmedicineHumansPharmacology (medical)IloprostProspective StudiesDosingInfusions IntravenousProspective cohort studySystemic Sclerosis Raynaud's phenomenon Iloprost Quality of lifeScleroderma SystemicDose-Response Relationship DrugVascular diseasebusiness.industryRaynaud DiseaseMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeAnesthesiaQuality of LifeFemalebusinessIloprostmedicine.drugRheumatology
researchProduct

Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: A multicentre validation study

2012

IntroductionThe early detection of systemic sclerosis (SSc) patients at high risk of developing digital ulcers could allow preventive treatment, with a reduction of morbidity and social costs. In 2009, a quantitative score, the capillaroscopic skin ulcer risk index (CSURI), calculated according to the formula ‘D×M/N2’, was proposed, which was highly predictive of the appearance of scleroderma digital ulcers within 3 months of capillaroscopic evaluation.ObjectivesThis multicentre study aims to validate the predictive value and reproducibility of CSURI in a large population of SSc patients.MethodsCSURI was analysed in 229 unselected SSc patients by nailfold videocapillaroscopy (NVC). All pati…

AdultMalemedicine.medical_specialtyValidation studypredictive model; capillaroscopic skin ulcer; systematic scelorisImmunologyRisk AssessmentGeneral Biochemistry Genetics and Molecular BiologySclerodermaMicroscopic AngioscopySclerodermaFingersRheumatologyInternal medicineRisk indexEpidemiologySkin UlcermedicineImmunology and AllergyHumansAgedSkinScleroderma SystemicReceiver operating characteristicbusiness.industrySystemicArea under the curveSkin ulcerMiddle Agedmedicine.diseaseConnective tissue diseaseSurgeryCapillariesEarly DiagnosisNailsFemalemedicine.symptombusinessEpidemiologic MethodsAlgorithms
researchProduct

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double-Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

2018

Objective: To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti–double-stranded DNA (anti-dsDNA) positive (≥30 IU/ml) at baseline. Methods: In this phase III, double-blind, placebo-controlled study (BEL112341; ClinicalTrials.gov identifier: NCT01484496), patients with moderate to severe SLE (Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index [SELENA–SLEDAI] score ≥8) were randomized (2:1) to receive weekl…

AdultMalemedicine.medical_specialtymedicine.drug_classInjections SubcutaneousPopulationImmunologyPlaceboAntibodies Monoclonal HumanizedGastroenterologySystemic Lupus ErythematosusSeverity of Illness Index03 medical and health sciences0302 clinical medicineDouble-Blind MethodRheumatologyInternal medicinemedicineHumansLupus Erythematosus SystemicImmunology and Allergy030212 general & internal medicineeducationAdverse effectskin and connective tissue diseases030203 arthritis & rheumatologyeducation.field_of_studyLupus erythematosusIntention-to-treat analysisbusiness.industryComplement C3DNAmedicine.diseaseBelimumabRheumatologyIntention to Treat AnalysisTreatment OutcomeAntibodies AntinuclearImmunology and Allergy; Rheumatology; ImmunologyCorticosteroidOriginal ArticleFemalebusinessmedicine.drug
researchProduct

Effects of a nonsurgical exercise program on the decreased mouth opening in patients with systemic scleroderma.

2004

The decreased mouth opening (microstomia) represents a frequent finding in patients with systemic scleroderma (SSD), but little information is available about the efficacy of nonsurgical management of this condition. The aim of this study is to assess the effects of a nonsurgical exercise program on the decreased mouth opening in a group of 10 SSD patients with severe microstomia (maximal mouth opening 0.1). At the end of the 18-week period, all patients commented that eating, speaking and oral hygiene measures were easier. The edentulous subjects also experienced less difficulty inserting their own dentures. These findings suggest that regular application of the proposed exercise program m…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentDentistryFacial MusclesSystemic sclerodermaOral hygieneStatistics NonparametricEatingPatient satisfactionSettore MED/28 - Malattie OdontostomatologicheMicrostomiamedicineDentitionHumansSpeechIn patientAdverse effectGeneral DentistryAgedsystemic sclerosis nonsurgical exerciseMouthScleroderma SystemicDentitionDenture Completebusiness.industryMicrostomiaMiddle Agedmedicine.diseaseOral HygieneExercise TherapyPatient SatisfactionPhysical therapyFemaleDenturesMouth EdentulousbusinessFollow-Up Studies
researchProduct